ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0249

Validation of the SIMPLE Index for Disease Activity of Systemic Lupus Erythematosus in Chinese Patients
Abstract Number: 0250

Lupus Nephritis and Renal Outcomes in African-Americans: The Accelerating Medicines Partnership Cohort Experience
Abstract Number: 0251

Dynamics of Anti-Nuclear Antibodies in a Longitudinal Study of a Large Systemic Lupus Erythematosus Cohort
Abstract Number: 0252

Corticosteroid and Opioid Use Remain High in Systemic Lupus Erythematosus Patients Receiving Biologic Therapy: A Retrospective Claims Database Analysis
Abstract Number: 0253

Serum Albumin as a Predictor of Proteinuria Recovery in Lupus Nephritis
Abstract Number: 0254

LLDAS (Low Lupus Disease Activity State) and Remission Prevent Damage Accrual in Systemic Lupus Erythematosus (SLE) Patients in a Primarily Mestizo Cohort
Abstract Number: 0255

Effect of Removing Haemolytic and Gastrointestinal Activity from the Operational Definition of the Lupus Low Disease Activity State – Implications for Use as a Trial Endpoint
Abstract Number: 0256

Patient Perspective of the Type 1 and 2 SLE Model: A Qualitative Study
Abstract Number: 0257

Application of Text Mining Methods to Identify Lupus Nephritis from Electronic Health Records
Abstract Number: 0258

Using Patient-Reported Outcomes Measures to Classify Patients with Systemic Lupus Erythematous
Abstract Number: 0259

Guillain-Barré Syndrome in Systemic Lupus Erythematosus – Results of a Nationwide Analysis
Abstract Number: 0260

Does Higher Quality of Care in SLE Improve Quality of Life?
Abstract Number: 0261

Predictors of Future Repeat Renal Biopsies in Patients with Lupus Nephritis and Influence of Repeat Biopsy in Flare Management: A Retrospective Study
Abstract Number: 0262

SLE Pregnancies: C4 as Predictor of Flares and Adverse Pregnancy Outcomes
Abstract Number: 0263

Factors Associated with Disease Activity Remission and Recurrence in Cutaneous Lupus Erythematosus

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].